Response to comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'

In 2016, we reported four substantial observations of APECED/APS1 patients, who are deficient in AIRE, a major regulator of central T cell tolerance (Meyer et al., 2016). Two of those observations have been challenged. Specifically, ‘private’ autoantibody reactivities shared by only a few patients but collectively targeting >1000 autoantigens have been attributed to false positives (Landegren, 2019). While acknowledging this risk, our study-design included follow-up validation, permitting us to adopt statistical approaches to also limit false negatives. Importantly, many such private specificities have now been validated by multiple, independent means including the autoantibodies’ molecular cloning and expression. Second, a significant correlation of antibody-mediated IFNα neutralization with an absence of disease in patients highly disposed to Type I diabetes has been challenged because of a claimed failure to replicate our findings (Landegren, 2019). However, flaws in design and implementation invalidate this challenge. Thus, our results present robust, insightful, independently validated depictions of APECED/APS1, that have spawned productive follow-up studies.

[1]  Y. Crow,et al.  Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome , 2018, The New England journal of medicine.

[2]  M. Juan,et al.  Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. , 2005, Journal of autoimmunity.

[3]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[4]  F. Gillardon,et al.  Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high‐density protein microarrays , 2008, Proteomics.

[5]  Mark S. Anderson,et al.  Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1 , 2016, Scientific Reports.

[6]  Mark S. Anderson,et al.  Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies' , 2019, eLife.

[7]  F. Rieux-Laucat,et al.  Type I interferon-mediated autoinflammation due to DNase II deficiency , 2017, Nature Communications.

[8]  Oliver S. Burren,et al.  A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes , 2014, Diabetes.

[9]  Mark S. Anderson,et al.  Projection of an Immunological Self Shadow Within the Thymus by the Aire Protein , 2002, Science.

[10]  Olli Simell,et al.  Innate Immune Activity Is Detected Prior to Seroconversion in Children With HLA-Conferred Type 1 Diabetes Susceptibility , 2014, Diabetes.

[11]  Y. Crow,et al.  Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α , 2018, Journal of visualized experiments : JoVE.

[12]  Naoki Kitabayashi,et al.  Brief Report: Blockade of TANK‐Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)–Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells , 2017, Arthritis & rheumatology.

[13]  A. Meager,et al.  IMMUNOREACTIVE α-INTERFERON IN INSULIN-SECRETING β CELLS IN TYPE 1 DIABETES MELLITUS , 1987, The Lancet.

[14]  N. Gilhus,et al.  Clinical and Serologic Parallels to APS-I in Patients with Thymomas and Autoantigen Transcripts in Their Tumors , 2014, The Journal of Immunology.

[15]  T. Battelino,et al.  IL‐6‐specific autoantibodies among APECED and thymoma patients , 2016, Immunity, inflammation and disease.

[16]  C. Cunningham-Rundles,et al.  AIRE expression controls the peripheral selection of autoreactive B cells , 2019, Science Immunology.

[17]  J. Perheentupa Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  Hedi Peterson,et al.  AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies , 2016, Cell.

[19]  P. Peterson,et al.  Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1 , 2006, PLoS medicine.

[20]  A. Crawley Susceptibility , 2021, GLQ: A Journal of Lesbian and Gay Studies.

[21]  S. Holland,et al.  Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases , 2016, Arthritis & rheumatology.

[22]  A. Munnich,et al.  Mitochondrial double-stranded RNA triggers antiviral signalling in humans , 2018, Nature.

[23]  F. Cetani,et al.  Abbreviations used: AD, , 2022 .

[24]  Hedi Peterson,et al.  Autoantibody Repertoire in APECED Patients Targets Two Distinct Subgroups of Proteins , 2017, Front. Immunol..